MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms

SIMPLE SUMMARY: Biliary tract cancer is a rare malignancy with poor overall survival. The majority of patients are faced with advanced disease stage. Cisplatin-based treatment schedules represent the mainstay of first-line therapeutic strategy, yet only a small portion of patients develop a treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Posch, Florian, Prinz, Felix, Balihodzic, Amar, Mayr, Christian, Kiesslich, Tobias, Klec, Christiane, Jonas, Katharina, Barth, Dominik A., Riedl, Jakob M., Gerger, Armin, Pichler, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392278/
https://www.ncbi.nlm.nih.gov/pubmed/34439151
http://dx.doi.org/10.3390/cancers13163996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392278/
https://www.ncbi.nlm.nih.gov/pubmed/34439151
http://dx.doi.org/10.3390/cancers13163996

Ejemplares similares